Thus, it is critical to recognise CPVT as an important differential diagnosis to LQTS, and to consider mutation screening of the RYR2 gene in patients who do not have a mutation in one of the LQTS-associated genes. This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia.